Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatments

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 119

Inclusion Criteria

Signed informed consent must be obtained prior to participation in the study., Subject is currently enrolled in a pre-defined Novartis-sponsored study and is receiving spartalizumab as single agent or in combination with other study treatment., Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator., Subject has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements., Subject is willing and able to comply with the scheduled visits and treatment plans.

Exclusion Criteria

Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the CPDR001X2X01B study., Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

A rollover study for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib alone or in combination with other agents

Phase 1

ovartis Pharma Services AG

Updated 10/6/2020

A rollover study for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib alone or in combination with other agents

Phase 1

ovartis Farmacéutica, S.A.

Updated 12/12/2016

An open-label, multi-center rollover protocol for patientswho have participated in a Novartis-sponsored ribociclib(LEE011) study and are continuing to benefit fromribociclib as single agent or in combination with otherinvestigational treatments

RecruitingPhase 1

ovartis Pharma AG

Updated 7/22/2024

An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments

Recruiting

ovartis

Updated 4/9/2024

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.

Phase 1

Intercept Pharmaceuticals, Inc.

Updated 10/13/2020

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

Phase 1

INTERCEPT PHARMACEUTICALS INC.

Updated 8/21/2023

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

Phase 1

Intercept Pharmaceuticals, Inc.

Updated 5/9/2022

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

Phase 1

Intercept Pharmaceuticals, Inc.

Updated 9/26/2023

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

Phase 1

Intercept Pharmaceuticals, Inc.

Updated 10/30/2023

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.

Phase 1

Intercept Pharmaceuticals, Inc.

Updated 10/6/2020

Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatments

Recruitment & Eligibility

Study & Design

Related Trials

A rollover study for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib alone or in combination with other agents

A rollover study for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib alone or in combination with other agents

An open-label, multi-center rollover protocol for patientswho have participated in a Novartis-sponsored ribociclib(LEE011) study and are continuing to benefit fromribociclib as single agent or in combination with otherinvestigational treatments

An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.

Clinical Trial Alerts

Clinical Trial Alerts